Compare EPAM Systems Inc (EPAM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? EPAM Systems Inc trades at $122.44 (market cap $5.91B), while Travere Therapeutics Inc. Common Stock trades at $54.58 (market cap $5.02B). The key difference: EPAM Systems Inc is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EPAM | TVTX | |
|---|---|---|
Market Cap | $5.91B | $5.02B |
Volume | 559,030 | 2,060,842 |
Sector | Technology | Health |
52-Week High | $221.40 | $67.52 |
52-Week Low | $76.04 | $26.79 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $5.28B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $118.40, up 2.51% today, with strong technical momentum as it approaches resistance near $120. The company demonstrates solid fundamentals with consistent earnings beats (Q2 2026 EPS of $3.38 vs. $3.16 expected) and improving cash flow from operations at $655M in 2025. Recent news highlights successful cloud infrastructure delivery for EU projects and activist investor Engine Capital pushing for share buybacks.
EPAM presents a balanced investment case with attractive valuation (P/E 15.55) and strong analyst support (59% buy ratings), though revenue growth remains modest and North American market challenges persist. The stock's current level near consensus price target suggests limited near-term upside without significant earnings catalysts.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
